Lifeline Biotechnologies Updates Company’s Website, FDA Consultant’s Report and Leeb Brokerage Services

Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today announced the completion of the updating and launch of its website, www.lbti.com.

Jim Holmes, Lifeline's CEO, said, “The website has been comprehensively updated providing extensive information on the company, its history and current affairs. The site includes: Company Information, Products & IP, Investor Relations, Publications and Whitepapers as well as Contact Forms. The updated information addresses many of the questions recently posed by the Company’s shareholders and interested parties. We believe you will find the new information about the Company and its First Warning System™ to be informative regarding important aspects of the Company and our business.

“Many of our shareholders are eager and looking forward to the pending FDA Consulting Firm’s report. We have been assured the report is nearing completion. We expect the report to guide us in the preparation and submission of our 510(k) application to the FDA. Clearance of the 510(k) will further our commercialization efforts to bring the First Warning System™ to market.

“Concerning the recent SEC action against Leeb Brokerage Services and several of its associates, we again confirm that the Company has no knowledge of or association with Leeb and its alleged illegal activities. The SEC action against Leeb has resulted in DTC suspending their services of Lifeline. We have been in communication with DTC and are in the process of providing them information that is expected to confirm that all trading shares issued by Lifeline are in accordance with regulatory requirements. If DTC agrees, then DTC services are expected to be reestablished for Lifeline.”

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.